Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    NX-5948

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nurix Therapeutics Reveals 2025 Financials And Corporate Update
    Nurix Therapeutics Reveals 2025 Financials And Corporate Update

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3228040/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    Nurix Therapeutics Sets 2026 Goals For Advancing Bexobrutideg
    Nurix Therapeutics Sets 2026 Goals For Advancing Bexobrutideg

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216702/0/en/Nurix-Therapeutics-Outlines-2026-Goals-and-Objectives-for-Advancing-Bexobrutideg-and-Its-Pipeline-of-Novel-Degrader-Based-Medicines-in-Cancer-and-Autoimmune-Diseases.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Nurix Presents Bexobrutideg Data in Waldenström at ASH
    Nurix Presents Bexobrutideg Data in Waldenström at ASH

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201481/0/en/Nurix-Therapeutics-Presents-New-Data-from-the-Phase-1-Trial-of-Bexobrutideg-NX-5948-in-Waldenstr%C3%B6m-Macroglobulinemia-at-the-67th-American-Society-of-Hematology-ASH-Annual-Meeting-a.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Nurix Shows Strong Responses In Phase 1 Bexobrutideg Trial
    Nurix Shows Strong Responses In Phase 1 Bexobrutideg Trial

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/06/3201064/0/en/Nurix-Therapeutics-Presents-New-Data-Demonstrating-Durable-Deepening-Responses-in-Phase-1-Trial-of-Bexobrutideg-NX-5948-in-Patients-with-Relapsed-or-Refractory-Chronic-Lymphocytic-.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Nurix Therapeutics To Present Phase 1 Bexobrutideg Data At ASH
    Nurix Therapeutics To Present Phase 1 Bexobrutideg Data At ASH

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196838/0/en/Nurix-Therapeutics-Announces-Webcast-to-Review-New-and-Updated-Data-from-the-Phase-1-Clinical-Trial-of-BTK-Degrader-Bexobrutideg-NX-5948-To-Be-Presented-at-the-67th-American-Societ.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.